tiprankstipranks
Advertisement
Advertisement

VRTX Stock Latest News

Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
RatingsVertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
23h ago
VRTX
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
PremiumThe Fly
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
1d ago
VRTX
Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss
PremiumThe Fly
Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss
2d ago
SION
VRTX
Vertex Pharmaceuticals price target raised to $672 from $605 at BofA
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $672 from $605 at BofA
2d ago
SION
VRTX
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
PremiumMarket News
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
2d ago
SION
VRTX
Early notable gainers among liquid option names on August 10th
PremiumThe FlyEarly notable gainers among liquid option names on August 10th
2d ago
APA
AKAM
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
Premium
The Fly
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
7d ago
VRTX
Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays
Premium
The Fly
Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays
7d ago
VRTX
Vertex Pharmaceuticals Ups 2026 Outlook Amid Heavy Investment
PremiumCompany Announcements
Vertex Pharmaceuticals Ups 2026 Outlook Amid Heavy Investment
7d ago
VRTX
Vertex: Strong Q2 Beat and Raised Revenue Outlook Underpin Buy Rating and Broadening Growth Beyond CF
PremiumRatings
Vertex: Strong Q2 Beat and Raised Revenue Outlook Underpin Buy Rating and Broadening Growth Beyond CF
8d ago
VRTX
Vertex: Buy Rating Reaffirmed with Unchanged $585 Price Target on Strong CF Performance and Late-Stage Pipeline Upside
PremiumRatings
Vertex: Buy Rating Reaffirmed with Unchanged $585 Price Target on Strong CF Performance and Late-Stage Pipeline Upside
8d ago
VRTX
Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
PremiumRatings
Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
8d ago
VRTX
Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
PremiumRatingsVertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
8d ago
VRTX
Vertex Upgraded to Buy as Strong Q2, Raised 2026 Guidance and Higher $605 Price Target Signal Durable, Diversified Growth
Premium
Ratings
Vertex Upgraded to Buy as Strong Q2, Raised 2026 Guidance and Higher $605 Price Target Signal Durable, Diversified Growth
8d ago
VRTX
Vertex Pharmaceuticals price target raised to $605 from $600 at BofA
Premium
The Fly
Vertex Pharmaceuticals price target raised to $605 from $600 at BofA
8d ago
VRTX
Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald
8d ago
VRTX
Vertex Pharmaceuticals price target raised to $550 from $525 at TD Cowen
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $550 from $525 at TD Cowen
8d ago
VRTX
Vertex Pharmaceuticals price target raised to $442 from $430 at Canaccord
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $442 from $430 at Canaccord
8d ago
VRTX
Vertex Pharmaceuticals price target raised to $500 from $466 at Stifel
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $500 from $466 at Stifel
8d ago
VRTX
Vertex Pharmaceuticals reports Q2 adjusted EPS $4.73, consensus $4.75
PremiumThe FlyVertex Pharmaceuticals reports Q2 adjusted EPS $4.73, consensus $4.75
9d ago
VRTX
Vertex Pharmaceuticals ups FY26 revenue view to $13.1B-$13.2B, consensus $13.05B
Premium
The Fly
Vertex Pharmaceuticals ups FY26 revenue view to $13.1B-$13.2B, consensus $13.05B
9d ago
VRTX
Vertex options imply 5.4% move in share price post-earnings
Premium
The Fly
Vertex options imply 5.4% move in share price post-earnings
9d ago
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >